Evolus vs Rigel Pharmaceuticals
EOLS and RIGL side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How EOLS and RIGL compare
Rigel Pharmaceuticals is the larger company, worth 1.8 times as much as Evolus ($831M against $460M).
Evolus grew revenue faster over the last twelve months (13.9% versus 2.2% for Rigel Pharmaceuticals).
Rigel Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of 107% compared with −9.6% at Evolus.
Rigel Pharmaceuticals scores higher on the StockData Score (11 against 6 for Evolus), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | EOLS | RIGL |
|---|---|---|
| Size and price | ||
| Market cap | $460M | $831M |
| Share price | $6.96 | $44.46 |
| Change, 1 year | −4.7% | 11.3% |
| Change, 5 years | 9.1% | 45.8% |
| Beta (5Y) | 1.13 | 1.08 |
| Employees | 334 | 174 |
| StockData Score | ||
| Total score | 6 | 11 (better) |
| Valuation score | 1 | 3 (better) |
| Growth score | 2 (better) | 1 |
| Performance score | 2 | 4 (better) |
| Health score | 1 | 3 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 2.9× |
| P/S | 1.4× (better) | 2.9× |
| P/B | – | 1.9× |
| EV/EBITDA | – | 9.2× |
| FCF yield | −1.1% | – |
| Growth | ||
| Revenue growth (TTM) | 13.9% (better) | 2.2% |
| Revenue growth, 5Y average | 39.4% (better) | 22.1% |
| Net income growth (TTM) | – | 171% |
| EPS growth (TTM) | – | 147% |
| Profitability | ||
| Gross margin | 66.4% | 89.6% (better) |
| Operating margin | −4.8% | 26.3% (better) |
| Net margin | −9.6% | 107% (better) |
| FCF margin | −1.5% | – |
| Return on equity | – | 109% |
| Return on invested capital | −16.3% | 46.4% (better) |
| Financial health | ||
| Interest coverage | −1.0× | 18.2× (better) |
| Current ratio | 1.42 | 2.39 (better) |
| Altman Z-score | −1.34 | 4.98 (better) |
| Piotroski F-score | 2 | 7 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 84.0% | 87.7% |
| Held by insiders | 4.1% | 3.3% |
| Insider net buying, 12 months | −$1.8M | −$306K (better) |
| Short interest, % of float | 9.5% | 14.0% |
Go deeper
- EOLS stock overview
- EOLS income statement
- EOLS valuation and score
- RIGL stock overview
- RIGL income statement
- RIGL valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.